Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden

References

• World Health Organization (WHO). About diabetes. http://www.who.int/diabetes/action_online/basics/en/. Accessed February 19, 2015
   Google Scholar
• 1177 Vårdguiden Stockholms Läns Landsting. Läkemedel vid Typ 1-diabetes. www.1177.se Accessed March 3, 2016
   Google Scholar
• The Swedish National Diabetes Register (NDR). Årsrapport - 2014 års resultat. 2015
   Google Scholar
• Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235–43
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859–67
   PubMed Web of Science ®Google Scholar
• Goldman J, White JR Jr. New insulin glargine 300 U/mL for the treatment of type 1 and type 2 diabetes mellitus. Ann Pharmacother 2015;49:1153–61
   PubMed Web of Science ®Google Scholar
• Davies MJ, Gagliardino JJ, Gray LJ et al. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med 2013;30:512–24
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010;4(1 Suppl):S11–S8
   Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682–9
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Evans JM, et al. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345–50
   PubMed Web of Science ®Google Scholar
• Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350:1505–10
   PubMed Web of Science ®Google Scholar
• Evans M, Jensen HH, Bogelund M, et al. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ 2013;16:1357–65
   PubMedGoogle Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ: HEPAC 2011;12:219–30
   PubMed Web of Science ®Google Scholar
• Higgins A, Barnett J, Meads C et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health 2014;17:877–87
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Quality Life Outcomes 2013;11:90
   PubMed Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267–73
   PubMed Web of Science ®Google Scholar
• Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Quality Life Outcomes 2008;6:73
   PubMed Web of Science ®Google Scholar
• Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ 2015;18:1-11
   Web of Science ®Google Scholar
• Bogelund M, Vilsboll T, Faber J, et al. Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment. Curr Med Res Opin 2011;27:2175–83
   PubMed Web of Science ®Google Scholar
• Guimaraes C, Marra CA, Colley L, et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care 2009;25:359–66
   PubMed Web of Science ®Google Scholar
• Jendle J, Torffvit O, Ridderstrale M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917–23
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Therapeut 2011;33:1258–67
   PubMed Web of Science ®Google Scholar
• Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics 2013;31:677–91
   PubMed Web of Science ®Google Scholar
• Cookson R. Willingness to pay methods in health care: a sceptical view. Health Econ 2003;12:891–4
   PubMed Web of Science ®Google Scholar
• Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007
   Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther 2016;18:252–7
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38:2217–25
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab 2015;17:1142–9
   PubMed Web of Science ®Google Scholar
• Bateman I, Carson R, Day B, et al. Economic Valuation with Stated Preference Techniques - A Manual UK Department for Transport. Cheltenham, UK: Edward Elgar Publishing Inc.; 2002
   Google Scholar
• Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res 2002;2:99–108
   PubMedGoogle Scholar
• Statistics Sweden [Swedish: Statistiska Centralbyrån (SCB)]. Återstående livslängd efter kön och ålder. Prognosår 2013–2110. www.statistikdatabasen.scb.se. Accessed February 2, 2016
   Google Scholar
• FASS. Produktresumé (SPC), Toujeo, Injektionsvätska, lösning i förfylld injektionspenna 300 enheter/ml. 2015; www.fass.se. Accessed January 28, 2016.
   Google Scholar
• Dental and Pharmaceuticals Benefits Agency [Swedish: Tandvårds-och läkemedelsförmånsverket (TLV)]. Genomgång av läkemedel vid diabetes. 2010;76
   Google Scholar
• Svensson M, Nilsson FO, Arnberg K. reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness. PharmacoEconomics 2015;33:1229–36
   PubMed Web of Science ®Google Scholar
• Hugosson K, Engström A. Threshold value for a QALY - correlation with disease severity and decision uncertainty. Value Health 2008;11:A49 PHP67
   Google Scholar
• Tyc K, Steitz JA. A new interaction between the mouse 5' external transcribed spacer of pre-rRNA and U3 snRNA detected by psoralen crosslinking. Nucleic Acids Res 1992;20:5375–82
   PubMed Web of Science ®Google Scholar
• The Riksbank [Swedish: Riksbanken]. http://www.riksbank.se/sv/Rantor-och-valutakurser. Accessed April 14, 2016
   Google Scholar
• Statistics Sweden [Swedish: Statistiska Centralbyrån (SCB)]. Sammanräknad förvärvsinkomst för boende i Sverige den 31/12 resp år (antal personer, medel-och medianinkomst samt totalsumma) efter region, kön, ålder och inkomstklass. År 1991-2013 (Urval: Medelinkomst, riket, båda köonen, totalt 20 år+, alla inkomstklasser, 2014). 2015. www.statistikdatabasen.scb.se. Accessed February 23, 2016
   Google Scholar
• Statistics Sweden [Swedish: Statistiska Centralbyrån (SCB)]. Utbildningsnivå för befolkningen efter inrikes/utrikes född, kön och åldersgrupp 2014 (urval: Population: Befolkningen 2014, 20-74 år). 2015. www.statistikdatabasen.scb.se Accessed December 15, 2015
   Google Scholar